CHORUS suPAR

Companion diagnostic for the selection of COVID-19 patients eligible for treatment with Anakinra

DIESSE

DIAGNOSTICS EVOLUTION

2022_FL.1017 | REV.00

Chorus suPAR

Immunoenzymatic method for the quantitative determination of suPAR using a disposable device applied to the CHORUS TRIO instruments. The test is performed in the serum and plasma of **COVID-19 patients** and is used to evaluate the severity of the infection and as **COMPANION DIAGNOSTIC** for the selection of **patients eligible** for treatment with **Anakinra**.

Benefits of suPAR test for COVID-19 patients[1]

- **Guiding appropriate treatment of high-risk patients:** suPAR levels > 6 ng/mL recognize the patients at risk for respiratory failure at an early disease stage
- **Improving patients' outcome:** significant prevention of death and progression to severe respiratory failure
- **Empowering clinical decision:** results within few hours after patient's hospitalization visit
- **Reducing health care cost:** Significant reduction in median time of ICU and ED stay

1.Kyriazopoulou et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine 2021; 27, 1752-1760. SAVE MORE STUDY

CHORUS advantages

- **Single test ready to use device**
- **Random access system**
- **Safe and easy to use**
- **No hidden costs No waste of reagents**

Main assay features

- Calibrator and control included in the kit
- **Calibration stability:** every new lot
- **Sample type:** serum and plasma
- **Assay Range:** 1.5 – 20 ng/mL
- **Interpretation of results:**

< 6 ng/ml: Patient with reduced risk of severe progression of COVID-19	≥ 6 ng/ml: Patient at high risk of severe progression of COVID-19, eligible for the treatment with Anakinra

NAME	TEST	CODE
CHORUS suPAR	36	*81412*

DIESSE
DIAGNOSTICS EVOLUTION